Business Model Breakdown
How Incyte Corp Makes Money
INCY
Market Cap
$20.8B
Profit Margin
26.7%
Employees
2,617
The Short Version
Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology, hematology, and inflammation and autoimmunity. It makes money by selling its approved products, most notably Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease, and Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo. The company also generates revenue through collaborations and licensing agreements for its compounds with other pharmaceutical companies, leveraging its deep research capabilities to develop innovative treatments and bring them to market.
Where the Revenue Comes From
Jakafi Product Sales (~60-70% of revenue)
Opzelura Product Sales (~15-20% of revenue)
Royalties and Collaboration Revenue (~10-15% of revenue)
Who buys: Healthcare providers, hospitals, pharmacies, and patients suffering from cancer, blood disorders, and autoimmune/inflammatory skin conditions.
Why It Works (Competitive Advantages)
- ✔Strong R&D capabilities and a diversified pipeline focused on high-need areas.
- ✔Established commercial infrastructure for successful drug launches and distribution.
- ✔Proprietary compounds and intellectual property (IP) protecting key drugs like Jakafi (until 2028) and Opzelura.
Economic Moat: Narrow (Intangible Assets/IP (strong patent protection for current products like Jakafi and Opzelura), Switching Costs (for patients on established treatments, particularly for chronic conditions), Brand Power (Jakafi is a well-recognized brand in myelofibrosis and other indications))
What Our Analysis Says
DVR Score as of June 6, 2026
Incyte (INCY) is a well-established large-cap biopharmaceutical company ($20.45B market cap) showing solid Q1 2026 performance with an 85.4% YoY EPS beat and positive pipeline updates for zilurgisertib and Opzelura. These factors suggest continued steady growth and operational strength. However, consistent with previous analysis, its current size and operational maturity in the biopharmaceutical sector make a 10x valuation increase to over $200B within 3-5 years highly improbable. While the company is well-managed and positioned for value-creating expansion through its robust pipeline and existing portfolio, its trajectory is more indicative of sustained incremental growth rather than disruptive, exponential returns typically seen in early-stage ventures. The positive Q1 results and pipeline progress, while encouraging, do not fundamentally alter the long-term 10x potential outlook.